Hongxia Wang

Dr. Hongxia Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2023 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
SWShufeng Wang
Shufeng Wang
THTingting He
Tingting He
HWHongxia Wang
Hongxia Wang

20 October 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YWYannan Wu
Yannan Wu
ZHZhonghan Hu
Zhonghan Hu
JYJiaqian Yang
Jiaqian Yang
RLRong Liu
Rong Liu
HLHaiyang Li
Haiyang Li
HWHongxia Wang
Hongxia Wang

17 July 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
Yuxi ZhaoYuxi Zhao
Yuxi Zhao
JLJunyi Li
Junyi Li
BZBo Zheng
Bo Zheng
WLWanshan Liu
Wanshan Liu
YWYaru Wang
Yaru Wang
JZJing Zuo
Jing Zuo
Ovarian cancer is the deadliest gynecological malignancy. The main obstacle in treating high‐grade serous ovarian cancer (HGSOC) is platinum resistance. The mechanistic interface between tumor metabolic reprogramming and platinum resistance remains undefined. We integrated proteomic and metabolomic profiling of 97 primary HGSOC tumors to map the molecular landscape. Unsupervised clustering identified three subtypes. Subtype 3 exhibited a higher platinum resistance rate (64.5%), as well as worse overall ( p = 0.001) and recurrence‐free ( p = 0.0001) survival. At the molecular level, both Subtypes 2 and 3 tumors displayed phenotypes of activated lipid metabolism. However, Subtype 3 tumors were unique, exhibiting potential divergence between lipid metabolism and bioenergetics. The arachidonic acid metabolism pathway was upregulated ( p = 2.0 × 10 −6 ), and the key enzyme cyclooxygenase‐2 (COX‐2) was overexpressed ( p < 0.001). Subtype 3 tumors exhibited an inflammation‐associated state with the highest infiltration of M2‐like macrophages ( p = 0.007). Single‐cell transcriptomics revealed increased expression of PTGS2 (encoding COX‐2, p = 0.001) and CD163 ( p < 2.2 × 10 −16 ) in macrophages from platinum‐resistant HGSOC. Multiplex immunofluorescence confirmed that platinum‐resistant tumors had a higher proportion of COX‐2 + cells in M2‐like macrophages ( p = 0.010). These findings define a high‐risk HGSOC subtype characterized by inflammation‐related lipid metabolism. This suggests targeting the arachidonic acid metabolism pathway as a way to overcome platinum resistance.